These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12234264)

  • 1. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
    Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
    Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
    Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Bumm K; Barlogie B; Lim SH
    Blood; 2002 Aug; 100(3):961-5. PubMed ID: 12130509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
    Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
    Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1.
    Chiriva-Internati M; Wang Z; Pochopien S; Salati E; Lim SH
    Int J Cancer; 2003 Dec; 107(5):863-5. PubMed ID: 14566839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells.
    Liu Y; Tian X; Jiang S; Ren X; Liu F; Yang J; Chen Y; Jiang Y
    Cell Immunol; 2015; 298(1-2):18-24. PubMed ID: 26300426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
    Chiriva-Internati M; Du J; Cannon M; Barlogie B; Yi Q
    Br J Haematol; 2001 Feb; 112(2):410-20. PubMed ID: 11167840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
    Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
    Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
    Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
    Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
    Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
    Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
    LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
    Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
    Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
    Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
    van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
    Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
    J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
    Front Immunol; 2019; 10():1792. PubMed ID: 31428094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.